Amphastar Pharmaceuticals
AMPH
109 hedge funds and large institutions have $397M invested in Amphastar Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 33 increasing their positions, 40 reducing their positions, and 9 closing their positions.
56% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 9
10% more capital invested
Capital invested by funds: $363M → $397M (+$34.8M)
5% more funds holding
Funds holding: 104 → 109 (+5)
1.02% more ownership
Funds ownership: 43.92% → 44.94% (+1%)
18% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$5.19M |
| 2 |
MWNA
Marshall Wace North America
New York
|
+$2.88M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.77M |
| 4 |
ACM
Argent Capital Management
St Louis,
Missouri
|
+$2.03M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$2.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$6.08M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.94M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$1.3M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1.21M |
| 5 |
Citigroup
New York
|
-$998K |
AMPH Hedge Fund Activity: Q4 2017 in Review
109 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q4 2017, worth a combined $397M — up 9.6% from $363M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new AMPH positions and 9 closed out — a net gain of 5 holders — while 33 added to existing stakes and 40 trimmed.
The largest buyer was Millennium Management, adding an estimated $5.19M. The largest seller was Invesco, cutting an estimated $6.08M.
- 109 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q4 2017, up from 104 in Q3 2017.
- Funds reported $397M of Amphastar Pharmaceuticals stock for Q4 2017, up 9.6% quarter-over-quarter.
- 14 funds opened new Amphastar Pharmaceuticals positions in Q4 2017 and 9 closed out, a net change of +5 holders.
- The largest Amphastar Pharmaceuticals buyer in Q4 2017 was Millennium Management, an estimated $5.19M added.
- The largest Amphastar Pharmaceuticals seller in Q4 2017 was Invesco, an estimated $6.08M sold.
Based on aggregated 13F filings for Q4 2017.